Urothelial Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Bladder Cancer (131)

›

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval PMLive - 2 days (New A1) darolutamide Sensitive : A1 PMLive - 2d	darolutamide Sensitive: A1 - Approval PMLive - 2 days darolutamide Sensitive : A1 PMLive - 2 days - (New A1)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	avelumab + talazoparib Sensitive: C3 – Early Trials JAMA Oncol - 1 week (New C3) avelumab + talazoparib Sensitive : C3 JAMA Oncol - 1wk	avelumab + talazoparib Sensitive: C3 – Early Trials JAMA Oncol - 1 week avelumab + talazoparib Sensitive : C3 JAMA Oncol - 1 week - (New C3)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	avelumab + talazoparib Sensitive: C3 – Early Trials JAMA Oncol - 1 week (New C3) avelumab + talazoparib Sensitive : C3 JAMA Oncol - 1wk	avelumab + talazoparib Sensitive: C3 – Early Trials JAMA Oncol - 1 week avelumab + talazoparib Sensitive : C3 JAMA Oncol - 1 week - (New C3)
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	olaparib Sensitive: B - Late Trials AstraZeneca Press Release - 2 weeks (New B) olaparib Sensitive : B AstraZeneca Press Release - 2wk	olaparib Sensitive: B - Late Trials AstraZeneca Press Release - 2 weeks olaparib Sensitive : B AstraZeneca Press Release - 2 weeks - (New B)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval Clin Cancer Res - 2 weeks (New B) olaparib Sensitive : A1 Clin Cancer Res - 2wk	olaparib Sensitive: A1 - Approval Clin Cancer Res - 2 weeks olaparib Sensitive : A1 Clin Cancer Res - 2 weeks - (New B)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval Clin Cancer Res - 2 weeks (New B) olaparib Sensitive : A1 Clin Cancer Res - 2wk	olaparib Sensitive: A1 - Approval Clin Cancer Res - 2 weeks olaparib Sensitive : A1 Clin Cancer Res - 2 weeks - (New B)
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval Clin Cancer Res - 2 weeks (New B) olaparib Sensitive : A1 Clin Cancer Res - 2wk	olaparib Sensitive: A1 - Approval Clin Cancer Res - 2 weeks olaparib Sensitive : A1 Clin Cancer Res - 2 weeks - (New B)
AKR1C3 expression	Prostate Cancer	AKR1C3 expression	Prostate Cancer	abiraterone acetate Resistant: C3 – Early Trials Oncologist - 3 weeks (New C3) abiraterone acetate Resistant : C3 Oncologist - 3wk	abiraterone acetate Resistant: C3 – Early Trials Oncologist - 3 weeks abiraterone acetate Resistant : C3 Oncologist - 3 weeks - (New C3)
CD70 expression	Renal Cell Carcinoma	CD70 expression	Renal Cell Carcinoma	ALLO-316 Sensitive: D – Preclinical SITC 2022 - 3 weeks (New D) ALLO-316 Sensitive : D SITC 2022 - 3wk	ALLO-316 Sensitive: D – Preclinical SITC 2022 - 3 weeks ALLO-316 Sensitive : D SITC 2022 - 3 weeks - (New D)
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	avelumab + CYNK-101 Sensitive: D – Preclinical SITC 2022 - 3 weeks (New D) avelumab + CYNK-101 Sensitive : D SITC 2022 - 3wk	avelumab + CYNK-101 Sensitive: D – Preclinical SITC 2022 - 3 weeks avelumab + CYNK-101 Sensitive : D SITC 2022 - 3 weeks - (New D)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide capsule Sensitive: A1 - Approval enzalutamide capsule Sensitive : A1	enzalutamide capsule Sensitive: A1 - Approval enzalutamide capsule Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	enfortumab vedotin Sensitive: A1 - Approval enfortumab vedotin Sensitive : A1	enfortumab vedotin Sensitive: A1 - Approval enfortumab vedotin Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
FGFR2 mutation	Urothelial Cancer	FGFR2 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1

Urothelial Cancer

Associations(1104)

Associations
(1104)